# A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

> **NCT05627362** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ipsen** · enrollment: 68 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** Elafibranor 80 mg
- **DRUG:** Elafibranor 120 mg
- **DRUG:** Placebo Matched to Elafibranor 80 mg
- **DRUG:** Placebo Matched to Elafibranor 120 mg

## Key facts

- **NCT ID:** NCT05627362
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-29
- **Primary completion:** 2026-08-28
- **Final completion:** 2026-08-28
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05627362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05627362, "A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05627362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*